Alkem Forensic Audit, October 21, 2026: Grant Thornton to Probe Alleged Fund Misappropriation

Alkem Laboratories told the stock exchanges on Wednesday evening that its audit committee has approved a forensic audit. The Alkem forensic audit is tied to what the company calls a recent incident of alleged misappropriation of funds by a former employee, and Grant Thornton Bharat LLP has been brought in to run it.

That’s about all the filing says. There’s no amount, no name, and no timeline. For a ₹59,000-crore-plus pharma company, that silence is the part investors will chew on today.

What the Alkem forensic audit will look at

The Regulation 30 disclosure filed with NSE says the audit committee met on October 21, 2026 and cleared the probe to examine the facts around the incident, find the root cause and recommend corrective steps.

Grant Thornton’s brief, as set out in the filing, covers three things:

• a preliminary review of electronically stored information (emails, files and other digital records);
• market intelligence on procurement handled by the former employee;
• an independent investigation of suspected irregularities in certain transactions affecting the company.

The word that stands out is procurement. The suspected problem sits in buying, not in sales or in the reported revenue line, at least going by what the company has disclosed so far. The filing also cites a SEBI circular dated January 30, 2026 that sets out what listed companies must tell the market when a forensic audit begins.

The letter was signed by Manish Narang, President – Legal, Company Secretary and Compliance Officer, and the company says a copy will go up on its website as Regulation 30(8) requires.

How the stock stood before the news

The disclosure landed after trading hours, so Wednesday’s price doesn’t reflect it. According to CNBC-TV18’s Alkem share price page, the stock was at ₹5,001 at 3:25 pm on October 21, down 0.06% from the previous close of ₹5,004. The day’s range was ₹4,891.50 to ₹5,050.50.

The same page shows a 52-week range of ₹4,738.50 to ₹5,933.50, a 3.85% fall in the share price over the last five trading sessions, and a market capitalisation of about ₹59,794 crore. It lists Alkem’s total operating revenue for the year ended March 31, 2026 at ₹9,663.91 crore.

So the stock was already sitting much closer to its 52-week low than its high when the filing came out.

What it means for shareholders

We’d keep this in proportion. A forensic audit into one former employee’s procurement is not the same as questions about a company’s books as a whole, and Alkem has not said the amount is material. But it hasn’t said it isn’t, either. Until the size of the alleged loss is known, the market has to guess, and markets usually guess on the cautious side.

The next things to watch are any follow-up filing on the findings, any comment from management when Alkem reports its September-quarter numbers, and whether the statutory auditor flags anything in the results. Our guide on pharma stocks to watch covers how we track the sector, and for another fresh pharma filing from the same evening, see our note on Dr Reddy’s Zytorvi approval.

Sources: Alkem Laboratories Regulation 30 disclosure filed with NSE (October 21, 2026); CNBC-TV18 Alkem Laboratories share price page (data as of 3:25 pm, October 21, 2026).

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.